Consensus on safety management of novel hormonal therapy for advanced prostate cancer
Sujun Han , Shudong Cheng , Degang Ding , Jianming Guo , Zhisong He , Baiye Jin , Zhigang Ji , Tianxin Lin , Yuanjie Niu , Weijun Qin , Benkang Shi , Jinkai Shao , Xi’nan Sheng , Qiang Wei , Xin Wang , Xinghuan Wang , Shujie Xia , Wanhai Xu , Qing Zou , Xiongbing Zu , Renu Eapen , Chi-Fai Ng , Hirotsugu Uemura , Hiroji Uemura , Cheol Kwak , Jae Young Joung , Marniza Saad , Edmund Chiong , Nianzeng Xing
UroPrecision ›› 2023, Vol. 1 ›› Issue (2) : 53 -71.
Consensus on safety management of novel hormonal therapy for advanced prostate cancer
Prostate cancer (PCa) is one of the most prevalent malignant tumors in men, accompanied by high incidence and mortality rates. Novel hormonal therapy (NHT) has emerged as the primary treatment for advanced PCa, providing noticeable clinical benefits. However, the diverse range of adverse events (AEs) associated with NHT may influence both treatment efficacy and patients’ quality of life. In light of the latest international clinical research evidence and recommendations from domestic and foreign guidelines, this consensus aims to provide a comprehensive overview of the common AEs experienced during NHT for advanced PCa patients. Additionally, it seeks to develop a hierarchical approach to more efficiently manage AEs, presenting valuable insights for clinical medication and adverse reaction management.
adverse event / novel hormonal therapy / prostate cancer / safety management
2023 The Authors. UroPrecision published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.
/
| 〈 |
|
〉 |
PDF
(650KB)
